Filter
1261
Text search:
drug
approval
Featured
95
374
Language
Document type
686
251
175
64
38
23
16
4
3
1
Countries
89
47
41
36
34
33
30
28
26
26
25
23
23
23
21
20
20
18
14
14
13
13
12
12
11
11
10
9
8
8
8
7
6
5
5
5
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
590
104
39
39
32
30
12
Toolboxes
127
100
72
71
64
55
47
25
24
22
19
18
17
16
14
12
12
10
9
7
4
4
4
1
1
Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program.
A Guide For Multicentre Trials in High-Burden Countries
54th directing council; 67th session of the regional Committee of WHO for the Americas
CD54/11, Rev. 1, 2 October 2015, Original: Spanish
Research Article
BMC Infectious Diseases 2012, 12:262; doi:10.1186/1471-2334-12-262
17–24 November 2015
4–15 February 2013
Report of a mission 20–24 April 2015
The Global Campaign Against Epilepsy “Out of the Shadows”
The National Tuberculosis Programme (NTP) of Rwanda (known as TB & ORD Division/IHDPC/RBC) is preparing to write their next National Strategic Plan and for this reason Rwanda was selected as a country to received technical assistance (TA) to conduct an assessment of their surveillance system using t
...
The Rwandan Ministry of Health recognizes the threat that Non-Communicable Diseases (NCDs) pose to health and development in Rwanda and in 2009 articulates strategies to respond to them in the Health Sector Strategic Plan 2012 - 2018 (HSSP3). Among other things, the plan calls for a national prevale
...
These guidelines have been developed to provide guidance to the Ministry of Health in managing applications for registration of human pharmaceutical products in Rwanda. It was compiled by the Technical Working Group (TWG) on Medicines Evaluation and Registration (MER) of the East African Community M
...
The purpose of these guidelines is to help health workers to participate in the process of continuous surveillance of safety and efficacy of the pharmaceutical products which are used in clinical practice, thus help to achieve the ultimate goal to make safer and more effective treatment available to
...
This document describes the key areas that national governments should consider for the introduction and scale-up of point-of-care (POC) diagnostics within national programmes, as new innovative POC technologies are being introduced into the market. The next steps taken to include these new innovati
...
Recent systematic reviews and meta-analysis of the impact of chemical-based mollusciciding (King et al., 2015, Sokolow et al., 2016) have concluded that regular mollusciciding is likely to contribute significantly towards elimination of schistosomiasis in high-risk areas. The WHO roadmap’s new foc
...
